Please assess the completion status of the following clinical trial:

Trial Title: A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients ≥18 years old~* Life expectancy of at least 2 months~* Off previous cancer therapy for at least 14 days, or 5 half-lives for noncytotoxic agents prior to first study treatment administration~* Patients must have a calculated creatinine clearance \>60 mL/min~* Acceptable hematologic, renal and liver functions and coagulation status parameters~Exclusion Criteria:~* Patients with GVHD requiring systemic immunosuppressive therapy~* Uncontrolled leptomeningeal disease, auto-immune hemolytic anemia and uncontrolled and clinical significant disease related metabolic disorder~* Clinically significant intravascular coagulation~* Treatment with other investigational drugs within 14 days prior to first study treatment administration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dose Escalation and Expansion (Type: EXPERIMENTAL): APTO-253 will be given in ascending doses in patients with relapsed or refractory AML or high risk MDS (escalation cohort), until the maximum tolerated dose or recommended dose is reached. Followed by up to 30 patients enrolled in the expansion cohort at the recommended dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).